This work is licensed under the Creative Commons Attribution 4.0 International License.
Quintana RA, Banchs J, Gupta R, Lin HY, Raj SD, Conley A, et al. Early evidence of cardiotoxicity and tumor response in patients with sarcomas after high cumulative dose Doxorubicin given as a continuous infusion. Sarcoma 2017; 2017: 7495914. doi: 10.1155/2017/7495914QuintanaRABanchsJGuptaRLinHYRajSDConleyAEarly evidence of cardiotoxicity and tumor response in patients with sarcomas after high cumulative dose Doxorubicin given as a continuous infusion. Sarcoma2017; 2017: 7495914. doi: 10.1155/2017/7495914Open DOISearch in Google Scholar
Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 2011; 377: 127-38. doi: 10.1016/S0140-6736(10)62231-3ColemanMPFormanDBryantHButlerJRachetBMaringeCCancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet2011; 377: 127-38. doi: 10.1016/S0140-6736(10)62231-3Open DOISearch in Google Scholar
Jones RL, Wagner AJ, Kawai A, Tamura K, Shahir A, Van Tine BA, et al. Prospective evaluation of doxorubicin cardiotoxicity in patients with advanced soft-tissue sarcoma treated in the ANNOUNCE phase III randomized trial. Clin Cancer Res 2021; 27: 3861-6. doi: 10.1158/1078-0432.CCR-20-4592JonesRLWagnerAJKawaiATamuraKShahirAVan TineBAProspective evaluation of doxorubicin cardiotoxicity in patients with advanced soft-tissue sarcoma treated in the ANNOUNCE phase III randomized trial. Clin Cancer Res2021; 27: 3861-6. doi: 10.1158/1078-0432.CCR-20-4592Open DOISearch in Google Scholar
Krone RJ, Van Tine BA. More data to support a cardiac-oncologic partnership. JACC CardioOncol 2023; 5: 128-30. doi: 10.1016/j.jaccao.2023.01.002KroneRJVan TineBA.More data to support a cardiac-oncologic partnership. JACC CardioOncol2023; 5: 128-30. doi: 10.1016/j.jaccao.2023.01.002Open DOISearch in Google Scholar
Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869-79. doi: 10.1002/cncr.11407SwainSMWhaleyFSEwerMS.Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer2003; 97: 2869-79. doi: 10.1002/cncr.11407Open DOISearch in Google Scholar
Mo Z, Deng Y, Bao Y, Liu J, Jiang Y. Evaluation of cardiotoxicity of anthracycline-containing chemotherapy regimens in patients with bone and soft tissue sarcomas: a study of the FDA adverse event reporting system joint single-center real-world experience. Cancer Med 2023; 12: 21709-24. doi: 10.1002/cam4.6730MoZDengYBaoYLiuJJiangY.Evaluation of cardiotoxicity of anthracycline-containing chemotherapy regimens in patients with bone and soft tissue sarcomas: a study of the FDA adverse event reporting system joint single-center real-world experience. Cancer Med2023; 12: 21709-24. doi: 10.1002/cam4.6730Open DOISearch in Google Scholar
Paulides M, Kremers A, Stohr W, Bielack S, Jurgens H, Treuner J, et al. Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: a report of the late effects surveillance system (LESS). Pediatr Blood Cancer 2006; 46: 489-95. doi: 10.1002/pbc.20492PaulidesMKremersAStohrWBielackSJurgensHTreunerJProspective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: a report of the late effects surveillance system (LESS). Pediatr Blood Cancer2006; 46: 489-95. doi: 10.1002/pbc.20492Open DOISearch in Google Scholar
Shamai S, Rozenbaum Z, Merimsky O, Derakhshesh M, Moshkovits Y, Arnold J, et al. Cardio-toxicity among patients with sarcoma: a cardio-oncology registry. BMC Cancer 2020; 20: 609. doi: 10.1186/s12885-020-07104-9ShamaiSRozenbaumZMerimskyODerakhsheshMMoshkovitsYArnoldJCardio-toxicity among patients with sarcoma: a cardio-oncology registry. BMC Cancer2020; 20: 609. doi: 10.1186/s12885-020-07104-9Open DOISearch in Google Scholar
Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol 2003; 10: 132-9. doi: 10.1067/mnc.2003.7MitaniIJainDJoskaTMBurtnessBZaretBL.Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol2003; 10: 132-9. doi: 10.1067/mnc.2003.7Open DOISearch in Google Scholar
Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 2009; 10: 391-9. doi: 10.1016/S1470-2045(09)70042-7AltenaRPerikPJvan VeldhuisenDJde VriesEGGietemaJA.Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol2009; 10: 391-9. doi: 10.1016/S1470-2045(09)70042-7Open DOISearch in Google Scholar
Bonita R, Pradhan R. Cardiovascular toxicities of cancer chemotherapy. Semin Oncol 2013; 40: 156-67. doi: 10.1053/j.seminoncol.2013.01.004BonitaRPradhanR.Cardiovascular toxicities of cancer chemotherapy. Semin Oncol2013; 40: 156-67. doi: 10.1053/j.seminoncol.2013.01.004Open DOISearch in Google Scholar
Khawaja MZ, Cafferkey C, Rajani R, Redwood S, Cunningham D. Cardiac complications and manifestations of chemotherapy for cancer. Heart 2014; 100: 1133-40. doi: 10.1136/heartjnl-2013-303713KhawajaMZCafferkeyCRajaniRRedwoodSCunninghamD.Cardiac complications and manifestations of chemotherapy for cancer. Heart2014; 100: 1133-40. doi: 10.1136/heartjnl-2013-303713Open DOISearch in Google Scholar
Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004; 109: 3122-31. doi: 10.1161/01. CIR.0000133187.74800.B9YehETTongATLenihanDJYusufSWSwaffordJChampionCCardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation2004; 109: 3122-31. doi: 10.1161/01.CIR.0000133187.74800.B9Open DOISearch in Google Scholar
Alvarez JA, Russell RR. Cardio-oncology: the nuclear option. Curr Cardiol Rep 2017; 19: 31. doi: 10.1007/s11886-017-0844-zAlvarezJARussellRR.Cardio-oncology: the nuclear option. Curr Cardiol Rep2017; 19: 31. doi: 10.1007/s11886-017-0844-zOpen DOISearch in Google Scholar
Al-Batran SE, Meerpohl HG, von Minckwitz G, Atmaca A, Kleeberg U, Harbeck N, et al. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology 2006; 70: 141-6. doi: 10.1159/000093005Al-BatranSEMeerpohlHGvon MinckwitzGAtmacaAKleebergUHarbeckNReduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology2006; 70: 141-6. doi: 10.1159/000093005Open DOISearch in Google Scholar
Alhaja M, Chen S, Chin AC, Schulte B, Legasto CS. Cardiac safety of pegylated liposomal doxorubicin after conventional doxorubicin exposure in patients with sarcoma and breast cancer. Cureus 2023; 15: e44837. doi: 10.7759/cureus.44837AlhajaMChenSChinACSchulteBLegastoCS.Cardiac safety of pegylated liposomal doxorubicin after conventional doxorubicin exposure in patients with sarcoma and breast cancer. Cureus2023; 15: e44837. doi: 10.7759/cureus.44837Open DOISearch in Google Scholar
Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the american heart association. Circulation 2018; 137: e30-e66. doi: 10.1161/CIR.0000000000000556MehtaLSWatsonKEBaracABeckieTMBittnerVCruz-FloresSCardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the american heart association. Circulation2018; 137: e30-e66. doi: 10.1161/CIR.0000000000000556Open DOISearch in Google Scholar
Shantakumar S, Olsen M, Vo TT, Norgaard M, Pedersen L. Cardiac dysfunction among soft tissue sarcoma patients in Denmark. Clin Epidemiol 2016; 8: 53-9. doi: 10.2147/CLEP.S100779ShantakumarSOlsenMVoTTNorgaardMPedersenL.Cardiac dysfunction among soft tissue sarcoma patients in Denmark. Clin Epidemiol2016; 8: 53-9. doi: 10.2147/CLEP.S100779Open DOISearch in Google Scholar
Ettinghausen SE, Bonow RO, Palmeri ST, Seipp CA, Steinberg SM, White DE, et al. Prospective study of cardiomyopathy induced by adjuvant doxorubicin therapy in patients with soft-tissue sarcomas. Arch Surg 1986; 121: 1445-51. doi: 10.1001/archsurg.1986.01400120095016EttinghausenSEBonowROPalmeriSTSeippCASteinbergSMWhiteDEProspective study of cardiomyopathy induced by adjuvant doxorubicin therapy in patients with soft-tissue sarcomas. Arch Surg1986; 121: 1445-51. doi: 10.1001/archsurg.1986.01400120095016Open DOISearch in Google Scholar
Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of anthracyclines. Front Cardiovasc Med 2020; 7: 26. doi: 10.3389/fcvm.2020.00026CardinaleDIacopoFCipollaCM.Cardiotoxicity of anthracyclines. Front Cardiovasc Med2020; 7: 26. doi: 10.3389/fcvm.2020.00026Open DOISearch in Google Scholar
Leger K, Slone T, Lemler M, Leonard D, Cochran C, Bowman WP, et al. Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy. Pediatr Blood Cancer 2015; 62: 123-7. doi: 10.1002/pbc.25206LegerKSloneTLemlerMLeonardDCochranCBowmanWPSubclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy. Pediatr Blood Cancer2015; 62: 123-7. doi: 10.1002/pbc.25206Open DOISearch in Google Scholar
Alpman MS, Jarting A, Magnusson K, Manouras A, Henter JI, Broberg AM, et al. Longitudinal strain analysis for assessment of early cardiotoxicity during anthracycline treatment in childhood sarcoma: a single center experience. Cancer Rep (Hoboken) 2023; 6: e1852. doi: 10.1002/cnr2.1852AlpmanMSJartingAMagnussonKManourasAHenterJIBrobergAMLongitudinal strain analysis for assessment of early cardiotoxicity during anthracycline treatment in childhood sarcoma: a single center experience. Cancer Rep (Hoboken)2023; 6: e1852. doi: 10.1002/cnr2.1852Open DOISearch in Google Scholar
Heemelaar JC, Speetjens FM, Al Jaff AAM, Evenhuis RE, Polomski EAS, Mertens BJA, et al. Impact of age at diagnosis on cardiotoxicity in high-grade osteosarcoma and Ewing sarcoma patients. JACC CardioOncol 2023; 5: 117-27. doi: 10.1016/j.jaccao.2022.11.016HeemelaarJCSpeetjensFMAl JaffAAMEvenhuisREPolomskiEASMertensBJAImpact of age at diagnosis on cardiotoxicity in high-grade osteosarcoma and Ewing sarcoma patients. JACC CardioOncol2023; 5: 117-27. doi: 10.1016/j.jaccao.2022.11.016Open DOISearch in Google Scholar
Tian Z, Yang Y, Yang Y, Zhang F, Li P, Wang J, et al. High cumulative doxorubicin dose for advanced soft tissue sarcoma. BMC Cancer 2020; 20: 1139. doi: 10.1186/s12885-020-07663-xTianZYangYYangYZhangFLiPWangJHigh cumulative doxorubicin dose for advanced soft tissue sarcoma. BMC Cancer2020; 20: 1139. doi: 10.1186/s12885-020-07663-xOpen DOISearch in Google Scholar
Ehrhardt MJ, Leerink JM, Mulder RL, Mavinkurve-Groothuis A, Kok W, Nohria A, et al. Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2023; 24: e108-e20. doi: 10.1016/S1470-2045(23)00012-8EhrhardtMJLeerinkJMMulderRLMavinkurve-GroothuisAKokWNohriaASystematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol2023; 24: e108-e20. doi: 10.1016/S1470-2045(23)00012-8Open DOISearch in Google Scholar
Yoon GJ, Telli ML, Kao DP, Matsuda KY, Carlson RW, Witteles RM. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol 2010; 56: 1644-50. doi: 10.1016/j.jacc.2010.07.023YoonGJTelliMLKaoDPMatsudaKYCarlsonRWWittelesRM.Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?J Am Coll Cardiol2010; 56: 1644-50. doi: 10.1016/j.jacc.2010.07.023Open DOISearch in Google Scholar
Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014; 27: 911-39. doi: 10.1016/j.echo.2014.07.012PlanaJCGalderisiMBaracAEwerMSKyBScherrer-CrosbieMExpert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr2014; 27: 911-39. doi: 10.1016/j.echo.2014.07.012Open DOISearch in Google Scholar
Celutkiene J, Pudil R, Lopez-Fernandez T, Grapsa J, Nihoyannopoulos P, Bergler-Klein J, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail 2020; 22: 1504-24. doi: 10.1002/ejhf.1957CelutkieneJPudilRLopez-FernandezTGrapsaJNihoyannopoulosPBergler-KleinJRole of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail2020; 22: 1504-24. doi: 10.1002/ejhf.1957Open DOISearch in Google Scholar
Oikonomou EK, Kokkinidis DG, Kampaktsis PN, Amir EA, Marwick TH, Gupta D, et al. Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Cardiol 2019; 4: 1007-18. doi: 10.1001/jamacardio.2019.2952OikonomouEKKokkinidisDGKampaktsisPNAmirEAMarwickTHGuptaDAssessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Cardiol2019; 4: 1007-18. doi: 10.1001/jamacardio.2019.2952Open DOISearch in Google Scholar
Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; 43: 4229-361. doi: 10.1093/eurheartj/ehac244LyonARLopez-FernandezTCouchLSAsteggianoRAznarMCBergler-KleinJ2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J2022; 43: 4229-361. doi: 10.1093/eurheartj/ehac244Open DOISearch in Google Scholar
Suerken CK, D’Agostino RB, Jr., Jordan JH, Melendez GC, Vasu S, Lamar ZS, et al. Simultaneous left ventricular volume and strain changes during chemotherapy associate with 2-year postchemotherapy measures of left ventricular ejection fraction. J Am Heart Assoc 2020; 9: e015400. doi: 10.1161/JAHA.119.015400SuerkenCKD’AgostinoRBJr.JordanJHMelendezGCVasuSLamarZSSimultaneous left ventricular volume and strain changes during chemotherapy associate with 2-year postchemotherapy measures of left ventricular ejection fraction. J Am Heart Assoc2020; 9: e015400. doi: 10.1161/JAHA.119.015400Open DOISearch in Google Scholar
Muehlberg F, Funk S, Zange L, von Knobelsdorff-Brenkenhoff F, Blaszczyk E, Schulz A, et al. Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy. ESC Heart Fail 2018; 5: 620-9. doi: 10.1002/ehf2.12277MuehlbergFFunkSZangeLvon Knobelsdorff-BrenkenhoffFBlaszczykESchulzANative myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy. ESC Heart Fail2018; 5: 620-9. doi: 10.1002/ehf2.12277Open DOISearch in Google Scholar
Jordan JH, Vasu S, Morgan TM, D’Agostino RB, Jr., Melendez GC, Hamilton CA, et al. Anthracycline-associated T1 mapping characteristics are elevated independent of the presence of cardiovascular comorbidities in cancer survivors. Circ Cardiovasc Imaging 2016; 9. doi: 10.1161/CIRCIMAGING.115.004325JordanJHVasuSMorganTMD’AgostinoRBJr.MelendezGCHamiltonCAAnthracycline-associated T1 mapping characteristics are elevated independent of the presence of cardiovascular comorbidities in cancer survivors. Circ Cardiovasc Imaging2016; 9. doi: 10.1161/CIRCIMAGING.115.004325Open DOISearch in Google Scholar
Neilan TG, Coelho-Filho OR, Shah RV, Feng JH, Pena-Herrera D, Mandry D, et al. Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy. Am J Cardiol 2013; 111: 717-22. doi: 10.1016/j.amjcard.2012.11.022NeilanTGCoelho-FilhoORShahRVFengJHPena-HerreraDMandryDMyocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy. Am J Cardiol2013; 111: 717-22. doi: 10.1016/j.amjcard.2012.11.022Open DOISearch in Google Scholar
Ibrahim EH, Stojanovska J, Hassanein A, Duvernoy C, Croisille P, Pop-Busui R, et al. Regional cardiac function analysis from tagged MRI images. Comparison of techniques: Harmonic-Phase (HARP) versus Sinusoidal-Modeling (SinMod) analysis. Magn Reson Imaging 2018; 54: 271-82. doi: 10.1016/j.mri.2018.05.008IbrahimEHStojanovskaJHassaneinADuvernoyCCroisillePPop-BusuiRRegional cardiac function analysis from tagged MRI images. Comparison of techniques: Harmonic-Phase (HARP) versus Sinusoidal-Modeling (SinMod) analysis. Magn Reson Imaging2018; 54: 271-82. doi: 10.1016/j.mri.2018.05.008Open DOISearch in Google Scholar
Ibrahim EH, Baruah D, Budde M, Rubenstein J, Frei A, Schlaak R, et al. Optimized cardiac functional MRI of small-animal models of cancer radiation therapy. Magn Reson Imaging 2020; 73: 130-7. doi: 10.1016/j. mri.2020.08.020IbrahimEHBaruahDBuddeMRubensteinJFreiASchlaakROptimized cardiac functional MRI of small-animal models of cancer radiation therapy. Magn Reson Imaging2020; 73: 130-7. doi: 10.1016/j. mri.2020.08.020Open DOISearch in Google Scholar
Ibrahim EH, Baruah D, Croisille P, Stojanovska J, Rubenstein JC, Frei A, et al. Cardiac magnetic resonance for early detection of radiation therapyinduced cardiotoxicity in a small animal model. JACC CardioOncol 2021; 3: 113-30. doi: 10.1016/j.jaccao.2020.12.006IbrahimEHBaruahDCroisillePStojanovskaJRubensteinJCFreiACardiac magnetic resonance for early detection of radiation therapyinduced cardiotoxicity in a small animal model. JACC CardioOncol2021; 3: 113-30. doi: 10.1016/j.jaccao.2020.12.006Open DOISearch in Google Scholar
Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002; 105: 539-42. doi: 10.1161/hc0402.102975CerqueiraMDWeissmanNJDilsizianVJacobsAKKaulSLaskeyWKStandardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation2002; 105: 539-42. doi: 10.1161/hc0402.102975Open DOISearch in Google Scholar
